The Effect of p.G2019S Mutation in the LRRK2 Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the GBA1 Gene
Journal of Integrative Neuroscience · 2024
DOI: 10.31083/j.jin2301016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Integrative Neuroscience, 2024. Verfasst von Tatiana S Usenko und 10 weiteren Autor:innen. Beteiligte Einrichtung: Molecular and Radiation Biophysics Division, Petersburg Nuclear Physics Institute Named by B.P. Konstantinov of National Research Center «Kurchatov I…. Hauptthemen laut MEDLINE: Glucosylceramidase, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Parkinson Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation Grant.
Abstract (Originalsprache)
Background
Mutations in the glucocerebrosidase (GBA1) and leucine-rich repeat kinase 2 (LRRK2) genes, encoding lysosomal enzyme glucocerebrosidase (GCase) and leucine-rich repeat kinase 2 (LRRK2), respectively, are the most common related to Parkinson’s disease (PD). Recent data suggest a possible functional interaction between GCase and LRRK2 and their involvement in sphingolipid metabolism. The aim of the present study was to describe the clinical course and evaluate the lysosomal enzyme activities and sphingolipid concentrations in blood of patients with PD associated with dual mutations p.N370S GBA1 and p.G2019S LRRK2 (p.N370S/GBA-p.G2019S/LRRK2-PD) as well as in blood of asymptomatic mutation carriers (p.N370S/GBA1-p.G2019S/LRRK2-carrier).
Methods
One patient with p.N370S/GBA1-p.G2019S/LRRK2-PD and one p.N370S/GBA1-p.G2019S/LRRK2-carrier were enrolled. GBA1-associated PD (GBA1-PD), LRRK2-associated PD (LRRK2-PD), sporadic PD (sPD) patients were described earlier by our research group. A neuropsychiatric examination of the p.N370S/GBA1-p.G2019S/LRRK2-PD patient was carried out using scales (Montreal Cognitive Assessment scale (MoCA), Mini-mental State Examination scale (MMSE), Frontal Assessment Batter scale (FAB), Hospital Anxiety, and Depression Scale (HADS), etc). Lysosomal enzyme activity (GCase, alpha-galactosidase [GLA], acid sphingomyelinase [ASMase], galactosylcerebrosidase [GALC]) and sphingolipid concentrations (hexasylsphingosine [HexSph], lysoglobotriaosylsphingosine [LysoGb3], lysosphingomyelin [LysoSM]) were assessed with high-performance liquid chromatography–tandem mass spectrometry in blood. The following comparison with the previously described groups of GBA1-PD and sPD patients were conducted.
Results
Clinical features of p.N370S/GBA1-p.G2019S/LRRK2-PD included an early age of onset of the disease (46 years) and mild cognitive and affective disorders (MMSE = 29, MoCA = 23), despite a long (24 years) course of the disease. Interestingly, no differences were found in hydrolase activity and lysosphingolipid concentrations between the p.N370S/GBA1-p.G2019S/LRRK2-PD patient and GBA1-PD patients. However, GCase activity was lower in these groups than in LRRK2-PD, sPD, and controls. Additionally, the p.N370S/GBA1-p.G2019S/LRRK2-PD patient was characterized by a pronounced decreased in ASMase activity and increased LysoSM concentration compared to the p.N370S/GBA1-p.G2019S/LRRK2-carrier (p = 0.023, p = 0.027, respectively).
Conclusions
Based on one patient, our results indicate a protective effect of the p.G2019S mutation in the LRRK2 gene on clinical course of p.N370S/GBA1-PD. The identified pronounced alteration of ASMase activity and LysoSM concentration in p.N370S/GBA1-p.G2019S/LRRK2-PD provide the basis for the further research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular and Radiation Biophysics Division, Petersburg Nuclear Physics Institute Named by B.P. Konstantinov of National Research Center «Kurchatov Institute»,188300 Gatchina, Russia.
- Department of Molecular Genetic and Nanobiological Technologies Research Center, Pavlov First Saint-Petersburg State Medical University, 197022 Saint Petersburg, Russia.
- Neurology Department, Pavlov First Saint-Petersburg State Medical University, 197022 Saint Petersburg, Russia.
- Hereditary Metabolic Diseases Laboratory, Research Centre for Medical Genetics, 115522 Moscow, Russia.
- Scientific and Clinical Center for Neurodegenerative Diseases and Botulinum Therapy, Institute of the Human Brain RAS, 197376 Saint Petersburg, Russia.
Förderung
- Russian Science Foundation Grant
Zitieren
APA
Usenko, T. S., Timofeeva, A., Beletskaia, M., Basharova, K., Baydakova, G., Bezrukova, A., Grunina, M., Emelyanov, A., Miliukhina, I., Zakharova, E., & Pchelina, S. (2024). The Effect of p.G2019S Mutation in the LRRK2 Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the GBA1 Gene. Journal of Integrative Neuroscience. https://doi.org/10.31083/j.jin2301016
Vancouver
Usenko TS, Timofeeva A, Beletskaia M, Basharova K, Baydakova G, Bezrukova A, et al. The Effect of p.G2019S Mutation in the LRRK2 Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the GBA1 Gene. Journal of Integrative Neuroscience. 2024. doi:10.31083/j.jin2301016
BibTeX
@article{Usenko2024,
author = {Usenko, Tatiana S and Timofeeva, Alla and Beletskaia, Mariia and Basharova, Katerina and Baydakova, Galina and Bezrukova, Anastasia and Grunina, Maria and Emelyanov, Anton and Miliukhina, Irina and Zakharova, Ekaterina and Pchelina, Sofya},
title = {The Effect of p.G2019S Mutation in the LRRK2 Gene on the Activity of Lysosomal Hydrolases and the Clinical Features of Parkinson's Disease Associated with p.N370S Mutation in the GBA1 Gene},
journal = {Journal of Integrative Neuroscience},
year = {2024},
doi = {10.31083/j.jin2301016}
}
EUVIMED